Immunological markers of frailty predict outcomes beyond current risk scores in aortic stenosis following transcatheter aortic valve replacement: Role of neopterin and tryptophan  by Csordas, Adam et al.
IJC Metabolic & Endocrine 10 (2016) 7–15
Contents lists available at ScienceDirect
IJC Metabolic & Endocrine
j ourna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -metabo l ic -and-endocr ineImmunological markers of frailty predict outcomes beyond current risk
scores in aortic stenosis following transcatheter aortic valve
replacement: Role of neopterin and tryptophanAdam Csordas a,⁎, Dietmar Fuchs b, Antonio H. Frangieh a, Gilbert Reibnegger c, Barbara E. Stähli a,
Martin Cahenzly a, Fabian Nietlispach a, Willibald Maier a, Francesco Maisano d, Ronald K. Binder a,
Christoph Liebetrau e, Won-Keun Kim e, Helge Möllmann e, Christian Hamm e, Thomas F. Lüscher a
a Department of Cardiology, University Heart Center Zuerich, Raemistrasse 100, CH-8091, Zuerich
b Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innrain 80, A-6020 Innsbruck, Austria
c Department of Physiological Chemistry, Medical University of Graz, Harrachgasse 21, A-8010 Graz, Austria
d Department of Cardiovascular Surgery, University Heart Center Zuerich, Raemistrasse 100, CH-8091, Zuerich
e Department of Cardiology, Kerckhoff Heart Center, Benekestrasse 2-8, D-61231 Bad Nauheim, Germany⁎ Corresponding author at: Department of Cardiology, U
Raemistrasse 100 8091 Zuerich, Switzerland.
E-mail address: adam.csordas@usz.ch (A. Csordas).
http://dx.doi.org/10.1016/j.ijcme.2015.11.002
2214-7624/© 2015 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 26 August 2015
Received in revised form 8 November 2015
Accepted 22 November 2015
Available online 25 November 2015Background: Frailty and associated comorbidities are often prohibitive surgical risk factors in symptomatic severe
aortic stenosis. Transcatheter aortic valve replacement (TAVR) is a viable treatment option for such patients.
However, biomarkers providing a precise estimate of individual vulnerability and hence pre-interventional risk
for mortality are not available in this heterogenous patient population. Neopterin, a pteridine synthesized by
activated macrophages, has been associated with prevalent frailty in elderly patients. Moreover, immune
activation-mediated tryptophan degradation has been suggested to reﬂect frailty and reduced life expectancy
in diverse chronic disease states.
Methods:We thus prospectively investigated a total of 185 patients undergoing TAVR and measured neopterin,
kynurenine, tryptophan, tyrosine and phenylalanine levels at baseline and at day 1–3 post intervention.
Royston-Parmar proportional hazards models were employed relating biomarkers to all-cause mortality.
Results: In bivariate analysis adjusted for EuroSCORE II, belonging to the upper quartile of neopterin (HR 5.7, 95%
CI: 2.0–16.5, P b 0.01), KTR (HR3.1, 95% CI: 1.1–8.5, P=0.02) andPhe/Tyr ratio (HR 2.8, 95%CI: 1.0–7.7, P=0.03)
emerged as independent predictors of mortality. A similar ﬁnding on neopterin and KTR was obtained in 207
patients of an independent external validation cohort.
Conclusions: Increased immune activation and associated tryptophan degradation serve as hallmarks of frailty
underscoring the prognostic role of baseline inﬂammation for outcome in patients with severe aortic stenosis
undergoing TAVR, and thus may provide a future therapeuthic target in this elderly patient population.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Neopterin
Tryptophan
Tavr
Risk prediction
Inﬂammation1. Introduction
Trancatheter aortic valve replacement (TAVR) has emerged as an
alternative treatment strategy in patients with severe aortic stenosis
deemed inoperable or at high surgical risk due to comorbidities [1,2].
Commonly used risk score algorithms such as the logistic EuroSCORE
II have exclusively been validated for short-termoutcome in surgical pa-
tients, and recent studies suggested poor accuracy of these surgical risk
scores in interventionally treated patients [3]. Consequently, allocation
of patients to either TAVR or surgical aortic valve replacement (SAVR) atniversity Heart Center Zuerich,
land Ltd. This is an open access articlpresent is mainly decided upon on the grounds of clinical assessment of
the patients' comorbidities.
In this regard, it has previously been suggested that pre-procedural
frailty serves as a signiﬁcant and independent discriminator of postop-
erative outcomes [4–6]. Moreover, geriatric risk scores proved to be
superior as compared to canonical surgical risk scores for the prediction
of death and functional decline following TAVR [7]. As uniform and
reproducible frailty assessment tools are not available, metabolomic
signatures associated with the frailty phenotype including increased
tryptophan degradation alongside elevated interleukin-6 and neopterin
levels may be useful [8–10].
Neopterin, a pteridine derivative mainly produced by activated
macrophages after induction by the Th1 cytokine interferon-γ has
been associated with plaque vulnerability [11], and increased neopterine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Moreover, as the catabolic effects of an increased inﬂammatory burden
may be a driving force towards frailty-associated physiological impair-
ments [14], both entities may share common biological pathways [15].
Accordingly, low serum albumin levels indicate a frail clinical phenotype
and correlatewith increasedmortality following TAVR [16,17]. Besides in-
creased secretion of neopterin, interferon-γ induces the expression of the
cytokine-responsive enzyme indoleamine 2,3-dioxygenase (IDO) which
initiates the degradation of the essential amino acid tryptophan via the
kynurenine pathway leading to an increased kynurenine/tryptophan
ratio (KTR). Additionally, chronic inﬂammation and immune activation
impairs tetrahydrobiopterin (THB) availability, leading to a reduced
conversion of phenylalanine to tyrosine [18]. Consequently, a lowphenyl-
alaninehydroxylase (PAH) functional activity as indicatedbyan increased
phenylalanine/tyrosine (Phe/Tyr) ratio reﬂects Th1-type immune activa-
tion. In contrast to upstream cytokines, neopterin, KTR and Phe/Tyr ratio
represent stable indicators of immune activation, enabling reliable
estimation of Th1-type immune activation [19,20]. However, these
markers have not been systematically explored in patients with severe
aortic stenosis deemed for TAVR.
In the present study, we embarked on an in-depth analysis of the
clinical relevance for Th1-type inﬂammatory markers including
neopterin, KTR and Phe/Tyr ratio as related to risk stratiﬁcation for
all-cause mortality in patients undergoing TAVR.2. Methods
2.1. Study population
Between September 2013 and December 2014, after giving written
informed consent, each patient older than 18 years of age awaiting
elective TAVR was included in the study on the day of admission at
the Department of Cardiology, University Heart Center Zuerich (usually
one day before surgery). Exclusion criteria were age b 18 years and
pre-existent infections (CRP N 20mg/L), such as urinary tract infections,
endocarditis, pneumonia or wound infections. A second cohort of 207
patients derived from the Kerckhoff Heart Center in Bad Nauheim,
Germany served as an external validation sample.
All patients were discussed in an interdisciplinary heart team, and
annual follow-up of patients was performed by study nurses and clinic
staff. The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki. Approval for the current study was obtained
from the Ethics Committee of the University of Zurich, and by the local
Ethics committee for the Kerckhoff Heart Center TAVR registry. An
independent critical event committee adjudicated all events of the
study cohort.2.2. Measurement of plasma biomarker levels
Serum sampleswere collected, frozen at the study site at−80 °C and
then shipped on dry ice to the Division of Biological Chemistry,
Biocenter, Innsbruck Medical University, where the specimens were
subsequently stored at−80 °C. Samples were also collected at postop-
erative days 1–3. Neopterin, kynurenine and amino acids were
measured as described previously [21].2.3. Clinical endpoints
The primary clinical endpoint for this analysis was all-causemortality.
Device success and early safety were calculated using criteria deﬁned by
the Valve Academic Research Consortium 2 (VARC 2) [22]. Procedure-
related complications including high degree AV-block necessitating pace-
maker implantation and outcome as related to post-procedural immune
activation were assessed as secondary endpoints.2.4. Statistical analyses
Plasma neopterin, KTR and Phe/Tyr ratio were measured at study
entry in 185 patients undergoing TAVR at the University Heart Center
Zuerich. In 121 patients, a complete time course entailing postoperative
day 1–3 was available. In the validation cohort, biomarkers were
measured at baseline in 207 patients. Normality was assessed with the
Kolmogorov-Smirnov test; for variables that signiﬁcantly differed from
normality, the Mann–Whitney U test was used. Discrete values were
expressed as counts (percentages) and continuous variables as means
(SD) or medians (IQR), as appropriate. Patients were dichotomized at
the upper quartile of baseline levels of neopterin, KTR and Phe/Tyr
ratio. For modeling the shape function of hazard rates, a ﬂexible para-
metric Royston-Parmar (RP) regression model with 2 degress of free-
dom (dfs) was employed [23]. To account for time-dependent hazard
rates, the grouping variable was included as a time-dependent covari-
ate. To delineate the time course of biomarkers following TAVR, a linear
mixed effects regression model with random intercepts was employed
with determination of an interaction between group (death: yes/no;
pacemaker: yes/no) and time. A prediction index (PI) was calculated
and categorized at the upper quartile. External validation of the PI was
carried out by application of the PI to the validation cohort, and compar-
ison of the predicted survival functionswith observedmortality (Kaplan
Meier estimates). The incremental prognostic utility of biomarkers was
evaluated by pooling both cohorts and calculating the integrated
discrimination improvement (IDI) and the category-free net reclassiﬁ-
cation improvement (NRI) with the corresponding 95% conﬁdence
intervals. The discriminative accuracy and model calibration were
assessed by the study center-adjusted Harrell's C-statistic and the
Hosmer-Lemeshow test, respectively. Calculated sample size was
estimated a priori by GPOWER 3.1 resulting in a requested number
of approximately 120 patients (given α= 0.05, power = 0.9, effect
size=0.25). All testswere two tailed; p b .05was considered signiﬁcant.
Stata Statistical Software (Release 13. College Station, TX: StataCorp LP)
was used for the statistical analyses.
3. Results
3.1. Baseline characteristics and distribution of biomarkers in the derivation
cohort.
Out of the 191 patients, 185 patients who fulﬁlled the inclusion
criteria were enrolled in this prospective cohort study. In all patients,
TAVR was performed via the transfemoral route using balloon expand-
able (SAPIEN XT or Sapien 3, n = 112) or self-expandable prostheses
(CoreValve, Medtronic, n = 56). In 17 patients, an alternative type of
valve was used. In the validation cohort, TAVR was performed via the
transfemoral route using balloon expandable (Edwards SAPIEN, n =
53) or self-expandable prostheses (CoreValve, Medtronic, n = 121). In
33 patients, an alternative type of valve was used.
The derivation cohortwas followed-up for 222 days (IQR124 – 394).
During this time period, 17 out of 185 patients died (9%). Baseline levels
of neopterin ranged from 4.3 nmol/L to 55.4 nmol/L, with a median of
13.4 nmol/L and 25th and 75th percentile values of 8.8 nmol/L and
19.7 nmol/L, respectively. Median EuroSCORE II, neopterin, KTR and
Phe/Tyr ratio values were sigiﬁcantly higher in patients who died
(Table 1). Within the study population, we found the expected correla-
tions between neopterin, KTR and Phe/Tyr ratio (Table 2). Serum albu-
min was negatively correlated with neopterin (r = −0.21, P b 0.01)
and KTR (r =−0.20, P = 0.02). Patients belonging to upper quartile
of neopterin (≥ 19.7 nmol/L) and KTR (≥ 54.5 μmol/mmol) had signiﬁ-
cantly lower serum albumin levels as compared to the lower quartiles
(median: 40 g/L lower quartiles; median: 36 g/L upper quartile for
neopterin, P b 0.01; median: 40 g/L lower quartiles, median: 37.5 g/L
upper quartile for KTR, P = 0.04). Moreover, we found a positive
correlation between albumin and tryptophan levels (r = 0.22, P =
Table 1
Baseline characteristics of the derivation study population according to all-cause mortality, upper quartile of neopterin and upper quartile of KTR.
Variables Total sample
(n = 185)
Deceased
(n = 17)
P-value Neopterin quartile
1–3 (b 19.7 nmol/L)
(n = 138)
Neopterin quartile
4 (≥ 19.7 nmol/L)
(n = 47)
P-value KTR quartile 1–3
(b 54.5 μmol/mmol)
(n = 139)
KTR quartile 4
(≥ 54.5 μmol/mmol)
(n = 46)
P-value
Clinical characteristics
Age,yrs. (median, IQR) 82 (77–89) 86 (82–88) 0.02 81 (77–85) 84 (81–89) b0.01 82 (77–85) 82.5 (78–88) 0.31
Male sex, n (%) 94 (51) 12 (71) 0.08 65 (47) 29 (62) 0.08 72 (52) 22 (48) 0.64
EuroSCORE II (median,
IQR)
3.2 (1.8–5.6) 5.9 (3.3–9.0) 0.01 2.9 (1.8–5.0) 5.5 (3.7–9.0) b0.01 3.0 (1.8–5.0) 4.9 (3.0–9.0) 0.01
BMI, kg/m2 (median, IQR) 27.0
(24.6–30.8)
24.6
(23.6–31.9)
0.68 27.2 (24.5 31.2) 26 (23.80–30.90) 0.39 26.7 (24.5-31.1) 27.3 (23.8-30.3) 0.87
Diabetes, n (%) 51 [28] 6 (35) 0.47 37 [27] 14 [30] 0.73 41 [30] 10 [22] 0.33
Hypertension 161 (87) 16 (94) 0.36 118 (86) 43 (91) 0.29 119 (86) 42 (91) 0.31
Atrial ﬁbrillation 63 (34) 7 (41) 0.52 40 [29] 23 (50) b0.01 40 [29] 23 (50) b0.01
Previous SAVR 8 [4] 1 [6] 0.74 5 [4] 3 [7] 0.40 4 [3] 4 [9] 0.09
Previous CABG 20 [11] 3 [18] 0.34 12 [9] 8 [17] 0.10 13 [10] 7 [15] 0.27
Previous CAD 94 (51) 13 (76) 0.02 62 (45) 32 (68) b0.01 67 (49) 27 (59) 0.23
Previous malignoma 31 [17] 4 [24] 0.44 22 [16] 9 [20] 0.57 22 [16] 9 [20] 0.57
Previous MI 21 [11] 4 [24] 0.09 12 [9] 9 [20] 0.04 13 [10] 8 [17] 0.14
Previous stroke 21 [11] 3 [18] 0.40 12 [9] 9 [20] 0.04 13 [10] 8 [17] 0.14
Renal failure1 99 (54) 14 (82) 0.01 59 (43) 40 (85) b0.01 61 (44) 38 (83) b0.01
COPD2 24 [13] 4 [25] 0.13 16 [12] 8 [17] 0.31 18 [13] 6 [13] 0.94
Peripheral arteriopathy 46 [25] 9 (53) b0.01 31 [22] 15 [32] 0.19 29 [21] 17 (37) 0.02
Pacemaker 11 [6] 0 0.27 9 [7] 2 [4] 0.59 6 [4] 5 [11] 0.10
Previous dialysis 1 [1] 0 0.74 0 1 [2] 0.07 0 1 [2] 0.08
NYHA functional class III/IV 117 (64) 12 (71) 0.52 83 (60) 34 (74) 0.09 86 (62) 31 (68) 0.50
Laboratory
Haemoglobin, g/dL
(mean, SD)
120.9 (18.6) 112.5 (20.4) 0.05 124.2 (17.5) 111.3 (18.6) b0.01 123.6 (18.4) 112.8 (16.8) 0.02
Creatinine, μmol/L
(median, IQR)
97.5
(77.5–117-5)
140
(104-165)
b0.01 91 (74-106) 133 (100-165) b0.01 91.5 (74-108) 128.5 (98-161) b0.01
Kynurenine, μmol/l
(median, IQR)
2.6 (2.0–3.2) 3. 0 (2.5–3.7) 0.02 2.4 (1.9–2.9) 3.2 (2.8–3.9) b0.01 2.4 (1.9–2.8) 3.4 (2.9–4.0) b0.01
Tryptophan, μmol/l
(median, IQR)
58.3
(50.3–67.9)
57.4
(51.7–61.9)
0.39 61.8 (51.7-69.7) 54.5 (46.4-60.7) 0.04 61.8 (52.8-69.4) 52.0 (44.9-59.2) b0.01
Phenylalanine, μmol/L
(median, IQR)
90.1
(80.1–108.3)
98.9
(84.9–108.2)
0.6 89.3 (79.5-107.2) 94.7 (84.9–111.7) 0.20 89.7 (80.1-107.7) 91.3 (80.7-115.7) 0.49
Tyrosine, μmol/L
(median, IQR)
138.4
(111.4–167.5)
118.9
(107.9–144.7)
0.19 142.6 (117.0–167.8) 129.0 (102.3–155.0) 0.13
Neopterin, nmol/l
(median, IQR)
13.4
(8.8–19.7)
22.7
(17.1–34.8)
b0.01 11.1 (8.5-15.5) 22.8 (18.2-29.5) b0.01
KTR, μmol/mmol
(median, IQR)
44.8
(36.9–54.5)
61.9
(45.6–83.7)
0.01 42.3 (35.7-48.1) 60.2 (51.1-75.3) b0.01
Phe/Tyr ratio, mol/mol
(median, IQR)
0.6 (0.5–0.7) 0.8
(0.6–0.8)
0.19 0.6 (0.5–0.7) 0.78 (0.6–0.8) b0.01 0.6 (0.5–0.7) 0.7 (0.6–0.8) b0.01
Echocardiography
LVEF b50, n (%) 58 [31] 4 [23] 0.46 41 [29] 17 (36) 0.41 44 [32] 14 [30] 0.87
Mean gradient, mmHg
(median, IQR)
42 (31–53) 45 (34–51) 0.81 42 (32–53) 36 (30–53) 0.26 42 (32–54) 35 (29–48) 0.07
Aortic valve area, cm2
(median, IQR)
0.7 (0.6–0.9) 0.7 (0.6–0.9) 0.88 0.7 (0.6–0.9) 0.71 (0.6–0.8) 0.59 0.7 (0.6–0.9) 0.76 (0.6–0.9) 0.99
1 GFR b 60ml/min. 2Long-term use of bronchodilatators or steroids. Abbreviations: GFR=glomerularﬁltration rate, SAVR= surgical aortic valve replacement, CABG=coronary artery
bypass grafting, MI =myocardial infarction, NYHA= New York Heart Association, COPD= chronic obstructive pulmonary disease, BMI = body mass index, CAD= coronary artery disease.
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higher rate of procedural complications (Table 3).
3.2. Relationship between inﬂammatory biomarkers and clinical outcomes.
Subjects in the upper quartile of neopterin (≥ 19.7 nmol/L) experi-
enced a signiﬁcantly higher rate of death as compared to subjects in
quartile 1–3 (23% vs. 4%, P b 0.01). Belonging to highest quartile of
neopterin retained its predicitve ability for mortality after adjusting
for baseline EuroSCORE II (HR 5.7, 95% CI: 2.0–16.5, P b 0.01). KTR was
also dichotomized at the upper quartile (≥ 54.5 μmol/mmol), and patients
in the upper KTR quartiles had a signiﬁcantly higher death rate as
compared to quartile 1–3 (20% vs. 6%, P b 0.01). In bivariate analysisTable 2
Spearman rank correlations (rs and P-values) between neopterin and amino acids in the deriv
Variable Tryptophan μmol/L Kynurenine μmol/l KTR μm
Neopterin nmol/L (n = 185) −0.2 (P b 0.01) 0.4 (P b 0.01) 0.6 (P badjusted for EuroSCORE II, also KTR remained a signiﬁcant predictor
for mortality (HR 3.1, 95% CI: 1.1–8.5, P = 0.02). Similarly, subjects
belonging to the upper quartile of Phe/Tyr ratio (≥ 0.8 mol/mol) experi-
enced signiﬁcantly higher event rates as compared to subjects belonging
to the lower quartiles (21% vs. 6%, P b 0.01). In bivariate analysis adjusted
for EuroSCORE II, Phe/Tyr ratio retained its predictive ability for mortality
(HR 2.8, 95% CI: 1.0–7.7, P = 0.03).
Besides analysis of the dichotomized cut-off values, the biomarkers
investigated were also assesed as continuous variables. After adjust-
ment for EuroSCORE II, a 1-unit increase in neopterin and KTR levels
was associated with increased risk of death. However, the Phe/Tyr
ratio lost signiﬁcance in this setting. Addition of neopterin and KTR
improved the discriminatory ability of the EuroSCORE II-based model.ation patient population
ol/mmol Phenylalanine μmol/L Tyrosine μmol/L Phe/Tyr ratio mol/mol
0.01) 0.1 (P = 0.38) −0.2 (P b 0.01) 0.3 (P b 0.01)
Table 3
Procedural complications oft the derivation patient population according to all-cause mortality, upper quartile of neopterin and upper quartile of KTR.
Variables
Total sample
(n = 185)
Deceased
(n = 17) P-value
Neopterin
quartile 1–3
(b19.7 nmol/L)
Neopterin
quartile 4
(≥19.7 nmol/L) P-value
KTR quartile 1–3
(b 54.5 μmol/mmol)
(n = 139)
KTR quartile 4
(≥ 54.5 μmol/mmol)
(n = 46) P-value
Device success, n (%) 177 (96) 11 (65) b0.01 133 (96) 44 (94) 0.42 133 (96) 44 (96) 0.99
Early safety, n (%) 175 (95) 10 (59) b0.01 132 (96) 43 (91) 0.27 133 (96) 42 (91) 0.25
Myocardial infarction,
n (%) 1 [1] 0 0.90 1 [1] 0 0.55 0 1 [2] 0.08
Emergency sternotomy,
n (%) 3 [2] 3 [18] b0.01 1 [1] 2 [4] 0.09 1 [1] 2 [4] 0.09
Major vascular
complications, n (%) 3 [2] 3 [18] b0.01 1 [1] 2 [4] 0.09 1 [1] 2 [4] 0.09
Life-threatening
bleeding, n (%) 3 [2] 3 [18] b0.01 1 [1] 2 [4] 0.09 1 [1] 2 [4] 0.09
All stroke (disabling and
non-disabling), n (%) 2 [1] 1 [1] 0.17 1 [1] 1 [2] 0.42 1 [1] 1 [2] 0.40
Need for pacemaker,
n (%) 35 [19] 34 [20] 0.27 24 [17] 11 [25] 0.27 25 [18] 10 [23] 0.51
Use of extracorporeal
membrane oxygenation,
n (%) 4 [2] 4 [24] b 0.01 2 [2] 2 [4] 0.25 2 [2] 2 [4] 0.24
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EuroSCORE II experienced the highest mortality rate (35% vs. 6%,
P b 0.01) (Table 4, Fig. 1).
3.3. Relationship between time course of inﬂammatory biomarkers and risk
of death.
Fig. 2 depicts the temporal trajectory of inﬂammatory biomarkers
following TAVR at days 1–3. Neopterin showed an initial drop after
day 1 (P b 0.01), which was followed by a non-signiﬁcant temporal
trajectory at day 2–3 (P N 0.05). On the other hand, Phe/Tyr ratio levels
signiﬁcantly increased at postoperative days 1–3 in the entire study
population (baseline/day 1–3: P b 0.01). KTR levels showed a non-
signiﬁcant increase at postoperative day 1 which was followed by a
decrease of KTR levels at day 2–3 (baseline/day 2–3: P b 0.05).
Patients who died exhibited an increase of neopterin at day 1–3 after
the procedure (neopterin: baseline/day 1–3: Pinteraction b 0.05). Similarly,
there was a signiﬁcantly steeper slope of Phe/Tyr ratio at postoperative
day 1 in subjects who died during follow-up as compared to survivors
(baseline/day1: Pinteraction = 0.04). Compared to survivors, KTR levels
showed a signiﬁcantly stronger rise at postoperative days 1–3 in patients
who died during follow-up (baseline/day 1–3: Pinteraction = b 0.05).
C-reactive protein (CRP) levels signiﬁcantly increased across all time
points investigated (P b 0.05). There was also a signiﬁcant interaction
between the time course of CRP and survivorship at postoperative day
2 and 3 (baseline/day 1–2: Pinteraction b 0.05). There was no signiﬁcantTable 4
RP-proportional hazards model with 2 dfs. Discriminatory ability of biomarker-enhanced mod
Variable Hazard ratio (95% Conﬁdence Inte
Univariate
EuroSCORE II (per 1 unit increase) 1.1 (0.9-1.1)
EuroSCORE II (upper quartile) 2.6 (1.0–6.9)
Neopterin nmol/L (per 1 unit increase) 1.1 (1.0–1.1)
Neopterin (upper quartile) 6.0 (2.2–16.3)
KTR μmol/mmol (per 1 unit increase) 1.1 (1.0–1.0)
KTR (upper quartile) 3.5 (1.3–9.2)
Phe/Tyr ratio mol/mol (per 1 unit increase) 5.9 (0.3–18.3)
Phe/Tyr ratio (upper quartile) 3.2 (1.2–8.6)
Bivariate
Neopterin nmol/L (per 1 unit increase) 1.0 (1.0–1.1)
Neopterin (upper quartile) 5.7 (2.0–16.5)
KTR μmol/mmol (per 1 unit increase) 1.0 (1.0–1.0)
KTR (upper quartile) 3.1 (1.1–8.5)
Phe/Tyr ratio mol/mol (per 1 unit increase) 4.6 (0.2–83.5)
Phe/Tyr ratio (upper quartile) 2.8 (1.0–7.7)interaction between the biomarkers investigated and need for postop-
erative pacemaker implantation or type of valve implanted. Also, there
was no signiﬁcant interaction with age and gender (P N 0.05 for all
biomarkers).
3.4. External validation cohort.
The baseline and procedural characteristics of the external validation
cohort are shown in Supplementary Tables 1–2. During one-year
follow-up, 37 patients died (18%). Elevated neopterin (≥ 24.4 nmol/L)
and KTR (≥ 62.5 μmol/mmol) levels (upper quartile) emerged also as
signiﬁcant predictors of mortality in the univariate (HR for neopterin:
1.9, 95% CI: 1.0–3.7, P = 0.03), (HR for KTR: 2.0, 95% CI: 1.0–3.7, P =
0.03) and bivariate (HR for neopterin: 2.0, 95% CI: 1.0–3.8, P = 0.02),
(HR for KTR: 2.0, 96% CI: 1.2–3.4, P = 0.04) analysis adjusted for
EuroSCORE II. Phe/Tyr ratio levels were not signiﬁcantly different
among subgroups according to survivorship (P N 0.05).
3.5. Incremental predictive value of inﬂammatory markers beyond
EuroSCORE II for one-year mortality.
To establish a biomarker-enhanced riskmodel for one-year all-cause
mortality, thederivation and validation cohortwere pooled and analysis
was restricted to patients who completed one-year follow-up (n =
296). All patients were censored after one year. For the EuroSCORE
II-based model, the area under-the-curve (AUC) was 0.62 (95% CI:els compared to existing risk schemes (EuroSCORE II).
rval) P-value C-index (95% CI) C-index difference (95% CI)
0.10 0.62 (0.53–0.82)
0.04
b0.01 0.79 (0.61–0.89) 0.17 (0.08-0.23)
b0.01
b0.01 0.75 (0.59–0.83) 0.13 (−0.03-0.22)
0.01
0.21 0.52 (0.42–0.71) −0.10 (−0.20-0.10)
0.01
b0.01 0.78 (0.61–0.81) 0.16 (0.07-0.21)
0.01
0.01 0.76 (0.58–0.84) 0.14 (−0.01-0.2)
0.02
0.30 0.53 (0.33–0.73) 0 (−0.22-0.12)
0.03
Fig. 1.Mortality rates of patients receiving TAVR, grouped by upper quartile of neopterin, EuroSCORE II andneopterin+EuroSCORE II. Results of a proportional hazards RP-model allowing
for time-dependent hazard rates with 2 dfs. (A) Hazard rates (B) Cumulative hazard rates (C) Cumulative survival probabilities. (D) Hazard ratio (ES II = EuroSCORE II).
Fig. 2. Longitudinal trajectories of neopterin, KTR, Phe/Tyr ratio and CRP at post-interventional day 1-3.Median and interquartile range of inﬂammatory biomarkers in patients after TAVR
according to postoperative mortality is shown.
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12 A. Csordas et al. / IJC Metabolic & Endocrine 10 (2016) 7–150.54–0.70). Addition of baseline neopterin and KTR to the EuroSCORE
II-based model led to improved discrimination (AUC = 0.78; 95% CI:
0.60–0.82 for the combined model with neopterin; AUC = 0.77; 95%
CI: 0.62–0.81 for the combined model with KTR). Phe/Tyr ratio levels
did not improve accuracy in discriminating between cases and controls.
The NRI and IDI indices for neopterin were 0.56 and 0.15, indicating
improved reclassiﬁcation. Likelihood ratio testing demonstrated a
signiﬁcantly improved model performance for the combined model
with neopterin and KTR as compared to the EuroSCORE II-based
model. There was no lack of calibration (Table 5, Fig. 3). Finally, we
established a prediction index for patients based on either EuroSCORE
II or a biomarker-enhanced (neopterin) model in the derivation data
set, and categorized the prediction index into two prognostic groups
based on the upper quartile of predicted risk. Model-basedmean survival
estimates and Kaplan-Meier curves for each prognostic group are shown
(Fig. 4). To evaluate the models` calibration in an independent data set,
the prediction index was ﬁt in the derivation cohort, and mean survival
functions in the same prognostic groups were calculated in the external
conﬁrmation cohort (Fig. 5).
4. Discussion
Here we for the ﬁrst time show that in an unselected contemporary
cohort of patients with severe symptomatic aortic stenosis undergoing
TAVR, baseline Th1-type inﬂammation markers including neopterin
and KTR were predictive for mortality beyond commonly used surgical
risk scores. While the neopterin-enhanced model enabled wide separa-
tion of prognoses among subgroups according to calculated risk, the
EuroSCORE II-based model performed remarkably poor in this regard
(Fig. 4). Consequently, the predictiveness curve of themodels including
neopterin and KTR showed a much steeper slope at the high the risk
spectrum than the univariate model, and their predictions aligned
signiﬁcantly better with the observed mortality rate as compared to
the EuroSCORE II-based model (Fig. 3). As the survival estimates of the
derivation cohort aligned well with the observed (Kaplan-Meier)
event rates in the external validation cohort, the calculated PI appeared
appropriately calibrated (Fig. 5).
Frailty, a multidimensional geriatric syndrome of increased vulnera-
bility to stressors and reduced physiologic reserve with resultant serious
adverse health outcomes, is strongly and independently associated with
incident mortality in patients undergoing TAVR [24]. Importantly, up to
one-third of those aged 80 and older are considered to be frail [25], and
current registry data have documented the limitations of surgical risk
scores for risk stratiﬁcation of TAVR patients [26]. However, as we lack
objective consensus deﬁnitions of this clinical phenotype, precise identiﬁ-
cation and quantiﬁcation of individual vulnerability remains an unre-
solved challenge in the clinical work up of patients deemed for TAVR.
The present study advances our understanding of the frailty phenotype
by providing insights into the degree of chronic systemic inﬂammation
and its relation to outcome in an unselected elderly patient population
following TAVR. As the aging process itself is associated with elevatedTable 5
Discrimination, calibration and reclassiﬁcation of biomarker-enhanced models compared to ex
Variable
C-index
(95% CI)
C-index difference
(95% CI)
Hosmer-L
(x2, P-valu
EuroSCORE II 0.62 (0.54–0.70) 9.1 (P = 0
Neopterin nmol/L 0.77 (0.58–0.81) 0.15 (0.04–0.21) 5.0 (P = 0
KTR μmol/mmol 0.76 (0.61–0.78) 0.14 (0.07–0.19) 6.8 (P = 0
Phe/Tyr mol/mol 0.52 (0.33–0.61) −0.10 (−0.20–0.10) 7.2 (P = 0
EuroSCORE II + Neopterin nmol/L 0.78 (0.60–0.82) 0.16 (0.06–0.23) 3.4 (P = 0
EuroSCORE II + KTR μmol/mmol 0.77 (0.62–0.81) 0.15 (0.08–0.22) 3.4 (P = 0
EuroSCORE II + Phe/Tyr mol/mol 0.59 (0.42–0.71) −0.03 (−0.12–0.11) 13.6 (P =
Abbreviations: IDI = integrated discrimination increment, NRI = net reclassiﬁcation index, LRcellular immune acitivation as evidenced by an age-related increase of
circulating neopterin and KTR levels [21,27], a further increase of these
inﬂammatory markers might be suggestive of a particularly vulnerable
clincal state with lower quartile values of these markers being associated
with a more robust clinical phenotype. As serum albumin levels were
signiﬁcantly lower in patients belonging to the upper neopterin and
KTR quartile, we believe that inﬂammation and associated frailty act
synergistcally as key demoniators of the substantial heterogeneity in
clinical outcomes within the elderly patient population.
The relationship between inﬂammation and reduced life expectancy
has been demonstrated in various disease states and diverse patient
populations [28]. Mechanistically, indoleamine 2,3-dioxygenase activa-
tion might lead to enhanced degradation and relative depletion of
tryptophan levels causing depression, cahexia and anaemia, all of
which have been linked to a reduced life expectancy [29–31]. Indeed,
in the present study, there was a positive correlation between albumin
and tryptophan levels, and patients belonging to the upper quartiles of
neopterin and KTR had signiﬁcantly lower haemoglobin levels than
those belonging to the quartile 1–3.
Patients who died within the follow-up period not only exhibited
elevated baseline inﬂammatory markers, but also a more pronounced
post-interventional immunological response than the remaining
patients who survived. As amaladaptive response to stressors is consid-
ered a cardinal feature of overall frailty, it can be speculated that an
exaggerated post-interventional inﬂammatory response could relate
to higher short-term risk for death as suggested by previous studies
[32]. Thus, anti-inﬂammatory strategies to limit an immunological
overactivation by the TAVR procedure should be evaluated in future
studies. In fact, the risk reduction afforded by statins in patients with
coronary heart disease was highest for those in the upper neopterin
quartile [33]. Whether these results obtained in different patient popu-
lations are also applicable to patients with aortic stenosis, comorbidities
and possibly frailty undergoing TAVR needs to be scrutinized in larger
patient cohorts.
4.1. Study Limitations.
The neopterin cut points used in the present study to deﬁne an
elevated level, was not speciﬁed a priori andwas based on an assessment
of quartiles of neopterin upon entry into the study. Moreover, given the
medium sample size, it was not possible to control for multiple baseline
and TAVR-related characteristics.
5. Conclusion
Overall, the present study suggests an incremental predictive value
of markers of inﬂammation and associated tryptophan degradation for
mortality in patients undergoing TAVR. Subclinical low-grade inﬂam-
mation appears to reﬂect a frail clinical condition associated with poor
life expectancy. Future clinical studies are required to further assess
whether neopterin and kynurenine/tryptophan ratio have a role in theisting risk schemes (EuroSCORE II) in the pooled patient cohort.
emeshow goodness of ﬁt
e)
LRT
(x2, P-value)
IDI
(95% CI)
NRI
(95% CI)
.32)
.75)
.55)
.50)
.90) 23.6 (P b 0.01) 0.15 (0.11–0.24) 0.56 (0.21–0.80)
.90) 20.0 (P b 0.01) 0.16 (0.09–0.28) 0.55 (0.19–0.83)
0.09) 0.46 (P = 0.49) 0 0.20 (−0.40–0.42)
T = likelihood ratio test.
Fig. 3. Predictiveness curves for the riskmodels investigated. Open cricles display observed proportions of deathwithin risk deciles. (A)Model based on EuroSCORE II. (B)Model based on
neopterin. (C) Model based on KTR. (D) Model based on Phe/Tyr ratio. (E) Model based on EuroSCORE II + KTR. (F) Model based on EuroSCORE II + neopterin (ES II = EuroSCORE II).
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and to further explore the role of inﬂammatory biomarkers as future
therapeuthic targets in a heterogenous elderly patient population
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